Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADAP01
- Development stage
- Preclinical
- Lead developer
- Adaptimmune Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
**ADAP01** is an undisclosed preclinical **CAR-T cell therapy** being developed by **Adaptimmune** in collaboration with **Noile-Immune** as part of a co-pipeline program. Based on the available pipeline information, the product is a target-specific engineered T-cell therapy intended to direct cytotoxic T-cell activity against tumor cells expressing an undisclosed antigen, but the precise target, cancer indication, construct design, and clinical setting have not been publicly disclosed. The program appears to remain in **preclinical development**.
Beyond the preview
Go deeper on ADAP01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADAP01.